Search

Displaying results 1691 - 1700 of 10000 in total
  1. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    Olmesartan is commonly used for the management of hypertension and Type 2 Diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors. … ARBs such as olmesartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression

    Mixtures: OPENVAS CO, ALMETEC-COCategories: Antihypertensive Agents Indicated for Hypertension, Agents Acting on the Renin-Angiotensin System
  2. Drug

    Clavulanic acid

    go.drugbank.com/drugs/DB00766
    ApprovedInvestigationalVet approved

    [A182228]When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.[L7880,L7904,L7910] … Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening

    Mixtures: Co-Amoxiclav for Injection 1.2g, JULMENTIN (2X 457 MG/5ML POWDER FOR SUSPENSION)
  3. Drug

    Cyclothiazide

    go.drugbank.com/drugs/DB00606
    Approved

    It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. … The antihypertensive mechanism of cyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance

  4. Drug

    Lactulose

    go.drugbank.com/drugs/DB00581
    ApprovedInvestigational

    and its first clinical use for treating PSE was not until 1966. … Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system[L6205], data regarding its optimal place in therapy is often ambiguous.

    Synonyms: 4-O-beta-D-Galactopyranosyl-D-fructose, 4-O-beta-D-Galactopyranosyl-D-fructofuranoseCategories: Drugs for Constipation
  5. Drug

    Josamycin

    go.drugbank.com/drugs/DB01321
    Investigational

    A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Josalid 250 mg/5 ml - Saft für Kinder, Josalid 375 mg/5 ml - Saft für Kinder
  6. Drug

    Choline salicylate

    go.drugbank.com/drugs/DB14006
    ApprovedNutraceutical

    The UK government has regulated its use, due to toxicity in those under 16 years of age. … Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers [L2134].

    Mixtures: ZYTEE-RB GEL
  7. Drug

    Urapidil

    go.drugbank.com/drugs/DB12661
    Investigational

    Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.

    Products: UPADİL 25 MG/5 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADET, UPADİL 50 MG/10 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADET
  8. Target

    Lysosomal protective protein

    go.drugbank.com/bio_entities/BE0008657
    EnzymeHumans

    Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability

    Synonyms: Protective protein for beta-galactosidase
  9. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication. … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.

  10. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use